Table 2.

Clinical characteristics of study patients by mutation status.

	N	Genetic status		Mutation breakdown
				OC genes				Other genes
		WTa	MUTb	BRCA1	BRCA2	MSH2	RAD51D	CHEK2	NBN
Number of subjects	47	32	13	10	1	1	1	1	1
Median age at dx (range)	37 (27–40)	36 (27–40)	38 (31–40)	37.5 (31–40)	40	38	34	40	38
Strong family historyc	17	9 (52.9%)	8 (47.1%)	7 (41.2%)	1 (5.9%)	0	0	0	NA
Personal hx of br ca	2	0	2 (100%)	2 (100%)	0	0	0	0	0
Optimally debulked (<1 cm)d
Yes	32	22 (68.8%)	10 (31.2%)	7 (21.9%)	1 (3.1%)	1 (3.1%)	1 (3.1%)	1	1
No	6	5 (83.3%)	1 (16.7%)	1 (16.7%)	0	0	0	0	0
Histology
HG serous	21	14 (66.7%)	7 (33.3%)	6 (28.6%)	1 (4.8%)	0	0	0	0
Undifferentiated carcinoma	2	1 (50%)	1 (50%)	1 (50%)	0	0	0	0	0
LG serous	7	7 (100%)	0	0	0	0	0	0	0
Endometrioid	7	3 (42.9%)	4 (57.1%)	2 (22.2%)	0	1 (11.1%)	1 (11.1%)	1 (11.1%)	1 (11.1%)
Clear cell	5	4 (80%)	1 (20%)	1 (20%)	0	0	0	0	0
Mucinous	3	3 (100%)	0	0	0	0	0	0	0
FIGO stagee
Stage I	5	4 (80%)	1 (20%)	0	0	0	1 (14.3%)	1 (14.3%)	1 (14.3%)
Stage II	5	3 (60%)	2 (40%)	1 (20%)	0	1 (20%)	0	0	0
Stage III	27	20 (74.1%)	7 (25.9%)	6 (22.2%)	1 (3.7%)	0	0	0	0
Stage IV	5	3 (60%)	2 (40%)	2 (40%)	0	0	0	0	0

Abbreviations:

OC = ovarian carcinoma, WT = wildtype, MUT = mutant, dx = diagnosis, NA = data not available, hx = history, br ca = breast carcinoma, HG serous = high grade serous (grade 2 or 3), LG serous = low grade serous (grade 1).

^aNo damaging mutations detected in any genes tested.

^bDamaging mutation detected in an “OC” gene.

^cA relative with OC, a relative with br ca < 50 years of age, or two relatives with br ca at any age.

^dTwo BRCA1, 5 WT have unknown debulking status.

^eStage was not available for three cases.